Outcomes of patients with end stage kidney disease on dialysis with COVID-19 in Abu Dhabi, United Arab Emirates; from PCR to antibody.
Wasim Ahmed, Ali Abdul Kareem Al Obaidli, Princy Joseph, Edward R Smith, Ayaz Ahmad Khan, Siddiq Anwar, Thangavelu Chandrasekar, Ayman Kamal Al Madani, Hormazdiar Dara Dastoor, Imran Zahid, Freddie Agbayani Costales, Yousef Abdul Rahim Boobes, Fatima Al Kindi, Salah Eldin Khalil Issa, Mohamed H Hassan, Abraham George, Stephen Geoffrey Holt
BMC Nephrology | Published : 2021
BACKGROUND: Individuals with end-stage kidney disease (ESKD) on dialysis are vulnerable to contracting COVID-19 infection, with mortality as high as 31 % in this group. Population demographics in the UAE are dissimilar to many other countries and data on antibody responses to COVID-19 is also limited. The objective of this study was to describe the characteristics of patients who developed COVID-19, the impact of the screening strategy, and to assess the antibody response to a subset of dialysis patients. METHODS: We retrospectively examined the outcomes of COVID19 infection in all our haemodialysis patients, who were tested regularly for COVID 19, whether symptomatic or asymptomatic. In add..View full abstract